In addition to being life-threatening, aortic aneurysms are difficult to assess. When one has been detected, the current standard of care to determine next steps is to look at an aneurysm’s size — if it’s beyond a certain size threshold, surgery is the recommended course of action. Unfortunately, size is an unreliable way to determine an aneurysm’s risk. The founders of ViTAA Medical Solutions are using innovations in AI and diagnostic imaging to assess aneurysms more accurately so that the right interventions can be taken.
UCalgary researchers Dr. Elena Di Martino, Schulich School of Engineering, and Dr. Randy Moore, Cumming School of Medicine, have been developing their innovative RAWTM (Regional Areas of Weakness) mapping technology to determine the strength of a patient’s aorta and provide surgeons with critical information to help them identify high-risk patients more precisely. After partnering with med-tech entrepreneur Steve Arless in 2019, ViTAA Medical Solutions was formed. Now with UCeed investment, the company will focus on getting regulatory approvals in the United States and Canada. Its ground-breaking technology will make a significant difference to patients with aortic aneurysms by ensuring they receive the most appropriate life-saving care more quickly while protecting lower-risk patients from unnecessary surgeries.
Visit ViTAA Medical Solutions’ website for more information.
ViTAA Medical Solutions has received investment from UCeed, a venture philanthropy fund accelerating UCalgary and community-based startup companies to advance problem-solving research, create jobs and fuel the economy. A key program in the UCalgary innovation ecosystem, UCeed bridges the gap between innovation, demonstration and commercialization, and is managed by UCalgary’s knowledge-transfer and business incubator, Innovate Calgary.
UCeed Health Fund is supported by the generosity of the River Fund at the Calgary Foundation and its mission to build a healthy and vibrant community where everyone belongs.